Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis b surface antigen
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepatitis B surface antigen (recombinant DNA) is a protein subunit vaccine consisting of the viral envelope protein of the Hepatitis B virus (HBV). Produced using recombinant DNA technology, typically in yeast (*Saccharomyces cerevisiae*), it is the primary component of standard prophylactic HBV vaccines such as Engerix-B and Recombivax HB. Beyond its established role in preventing HBV infection, this antigen has been investigated by the Klinikum der Universitaet Muenchen AöR (University of Munich) as a therapeutic vaccine candidate for the treatment of chronic hepatitis B. In a therapeutic context, the antigen is intended to overcome immune tolerance in chronically infected patients, stimulating the production of anti-HBs antibodies and activating T-cell mediated responses to reduce viral load and achieve functional cure. These applications often involve specialized adjuvants or heterologous prime-boost strategies to enhance immunogenicity.
- Brand names
- Engerix-BRecombivax HBElovac BGeneVac-BShanvac-B
- Other names
- HBsAgHepatitis B surface antigen (recombinant)Hepatitis B surface antigen (recombinant DNA)
Beyond the preview
Go deeper on hepatitis b surface antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis b surface antigen.